Femasys Q2 Sales Fall 19%, Net Loss Narrows; $30M Placement Funds FemBloc Push
FEMY is trading near its 52-week low of $2.19 (7.2% above the low).
Summary
Femasys reported Q2 2026 sales of $331,827, down 18.9% year-over-year, while net loss narrowed to $4.47M from $4.59M, with a loss per share of $1.33. The company highlighted the $30M private placement completed after quarter-end, which management says funds the U.S. commercial launch of FemaSeed and the FemBloc clinical program toward FDA approval. Recent milestones include CE Mark for FemHSG Catheter, initial commercial use of FemaSeed Complete, and a new COO. Cash was only $1.4M at June 30, so the $30M raise is critical to operations. The stock trades at a $6.9M market cap, reflecting deep skepticism about execution.
At the time of this announcement, FEMY was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $2.19 to $22.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.